MARKET

RDY

RDY

Dr.Reddys
NYSE

Real-time Quotes | Nasdaq Last Sale

74.06
+1.45
+2.00%
After Hours: 74.06 0 0.00% 16:00 06/11 EDT
OPEN
73.00
PREV CLOSE
72.61
HIGH
74.11
LOW
72.88
VOLUME
168.06K
TURNOVER
--
52 WEEK HIGH
74.11
52 WEEK LOW
51.12
MARKET CAP
12.28B
P/E (TTM)
42.27
1D
5D
1M
3M
1Y
5Y
Global Response Aid Reports Midyear Sales Results for COVID Drug
, UAE, /PRNewswire/ -- Healthcare solutions provider Global Response Aid (GRA) today reported seven-month global sales figures for its anti-viral tablet Avigan®/Reeqonus™, a drug being used in several countries to treat patients with mild to moderate case...
PR Newswire - PRF · 06/03 14:00
Dr. Reddy's in talks to bring single-dose Sputnik Light vaccine
Dr. Reddy's Laboratories (RDY) has started talks with the government to bring Russia's Sputnik Light COVID-19 vaccine into the country, a company spokesperson has told Reuters.A positive outcome could make Sputnik
Seekingalpha · 05/31 12:09
India's Dr. Reddy's in talks with government to bring Russia's Sputnik Light COVID-19 vaccine
India's Dr. Reddy's Laboratories is in talks with the government to bring Russia's Sputnik Light COVID-19 vaccine into the country, a company spokesperson told Reuters on Monday.
Reuters · 05/31 08:14
COVID-19 vaccines from Pfizer/BioNTech, JNJ and Moderna set for India entry as India clears hurdles
India has dropped the requirement to conduct local trials for "well-established" foreign COVID-19 vaccines in a move aimed at accelerating its immunization drive, Reuters reports.Despite a decline of daily new coronavirus
Seekingalpha · 05/27 21:27
India's vaccine output likely to fall short of target, sources say
reuters.com · 05/20 12:14
Dr Reddy's Laboratories Receives Emergency Use In India For Drug 2-Deoxy-D-glucose (2DG), Developed By INMAS
https://twitter.com/EconomicTimes/status/1395051555951239171
Benzinga · 05/19 16:23
Dr. Reddy's Laboratories' Price Target From Nomura Raised to INR6,145 From INR5,065, Buy Rating Maintained
MT Newswires · 05/18 09:15
Dr. Reddy's (RDY) Q4 Earnings Decline Y/Y, Sales Increase
Zacks.com · 05/17 16:17
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of RDY. Analyze the recent business situations of Dr.Reddys through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average RDY stock price target is 80.78 with a high estimate of 81.55 and a low estimate of 80.00.
EPS
Institutional Holdings
Institutions: 212
Institutional Holdings: 21.31M
% Owned: 12.85%
Shares Outstanding: 165.77M
TypeInstitutionsShares
Increased
54
2.01M
New
22
356.54K
Decreased
48
1.90M
Sold Out
37
673.81K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.92%
Pharmaceuticals & Medical Research
-0.72%
Key Executives
Chairman/Director
Satish Reddy
Co-Chairman/Managing Director/Director
G. Prasad
Chief Executive Officer
Erez Israeli
Corporate Executive
MARC KIKUCHI
Chief Financial Officer
Parag Agarwal
Corporate Executive
Patrick Aghanian
Corporate Executive
Marc Kikuchi
Corporate Executive
M. Ramana
Chief Human Resource Officer
Archana Bhaskar
Other
Raymond De Vre
Other
Sauri Gudlavalleti
Other
Ganadhish Kamat
Other
Anil Namboodiripad
Other
YUGANDHAR PUVVALA
Other
Yugandhar Puvvala
Other
Deepak Sapra
Other
SANJAY SHARMA
Other
Sanjay Sharma
Secretary
Sandeep Poddar
Non-Executive Independent Director
Bruce Carter
Non-Executive Independent Director
Bharat Doshi
Non-Executive Independent Director
Sridar Iyengar
Non-Executive Independent Director
Prasad Menon
Non-Executive Independent Director
Kalpana Morparia
Non-Executive Independent Director
Allan Oberman
Non-Executive Independent Director
Leo Puri
Non-Executive Independent Director
Shikha Sharma
Declaration Date
Dividend Per Share
Ex-Div Date
06/26/2020
Dividend USD 0.2769603
07/10/2020
--
Dividend USD 0.262229
07/12/2019
--
Dividend USD 0.272
07/13/2018
08/04/2017
Dividend USD 0.294
07/13/2017
08/03/2016
Dividend USD 0.279
07/14/2016
08/11/2015
Dividend USD 0.293
07/08/2015
08/08/2014
Dividend USD 0.272
08/01/2014
--
Dividend USD 0.283
07/09/2014
08/08/2013
Dividend USD 0.225
07/10/2013
  • All
  • Financials
  • Insiders
More
About RDY
Dr. Reddy's Laboratories Limited is a pharmaceutical company that is engaged in providing medicines. The Company operates in three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment includes manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics). PSAI segment includes the Company's business of manufacturing and marketing active pharmaceutical ingredients and intermediates (API) or bulk drugs. Proprietary Products segment focuses on the research, development and manufacture of differentiated formulations and new chemical entities. These products fall within the dermatology and neurology therapeutic areas, and are marketed and sold through its subsidiary, Promius Pharma, LLC.

Webull offers kinds of Dr Reddy's Laboratories Ltd (ADR) stock information, including NYSE:RDY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RDY stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading RDY stock methods without spending real money on the virtual paper trading platform.